GSK Raises 2025 Outlook on Strong HIV and Cancer Drug Sales

British pharmaceutical giant GSK has lifted its full-year 2025 guidance after a strong third quarter. Sales jumped thanks to double-digit growth in its HIV and cancer drug portfolios. 

The company reported Q3 revenue of about £8.55 billion, beating market expectations. Core earnings per share reached 55 pence, up significantly from the same quarter last year. 

GSK now expects annual revenue growth of 6%–7%, up from its earlier forecast of 3%–5%. It also raised its core earnings per share guidance to 10%–12% growth, compared to 6%–8% previously. 

Strong performance in Specialty Medicines led the gains. Oncology sales soared 39% and the HIV division grew 12%. Vaccines and general medicines posted smaller gains. 

The company is transitioning leadership next year, with Luke Miels set to take over as CEO. GSK faces challenges including U.S. trade tariffs and the upcoming loss of patent protections for key drugs. 

Investors greeted the news positively, sending GSK shares to their highest levels since mid-2024, as the company strengthens its growth strategy and late-stage drug pipeline.